FTC Fights Nixing Of AndroGel Reverse Payment Suit

By Erin Marie Daly · June 10, 2010, 7:06 PM EDT

The Federal Trade Commission is challenging the dismissal of its claims accusing Solvay Pharmaceuticals Inc. of paying generic-drug makers not to compete with its testosterone supplement AndroGel, continuing the fight over...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Appeal

Case Information

Case Title

IN RE: Androgel Antitrust Litigation (No. II)

Case Number

Court

Georgia Northern

Nature of Suit

Anti-Trust

Date Filed

October 05, 2009

Recent Articles By Erin

May 19, 2011
Genentech Sues Apotex Over Generic Valcyte
May 19, 2011
CORRECTED: Mylan's Inequitable Conduct Claim Axed In Vytorin IP Suit
May 18, 2011
Firms, Experts Allowed To Stay In AndroGel MDL
May 10, 2011
Pharmacies Attack $68B Pfizer-Wyeth Deal In 9th Circ.
May 03, 2011
2nd Circ. Rejects Nurses Review Of Class Cert. Denial
April 27, 2011
Genzyme Sues Over Endo's Bid To Sell Generic Renvela
April 27, 2011
Asahi, Actelion Throw Final Punches In Fasudil IP Row
April 20, 2011
Novartis Targets Teva Over Myfortic Patents
April 13, 2011
HGS Fires Round 2 At Genentech Over Lupus Drug IP
April 13, 2011
MetroPlus, HHC Evade State Claims In OT Action